

Edible dry bean consumption (*Phaseolus vulgaris* L.) modulates cardiovascular risk factors and diet-induced obesity in rats and mice

Zongjian Zhu, Weiqin Jiang and Henry J. Thompson*

Cancer Prevention Laboratory, Colorado State University, 1173 Campus Delivery, Fort Collins, CO 80523, USA

(Submitted 25 July 2011 – Accepted 16 September 2011)

Abstract

Pulses are grain legumes that have sustained the civilisations of the world throughout their development; yet this staple food crop has fallen into disuse, particularly in Westernised societies, and decreased consumption parallels increased prevalence of CVD. The objective of the present study was to identify mechanisms that account for the cardioprotective activity of dry bean (*Phaseolus vulgaris* L.), one of the four primary pulse crops, which is widely produced and consumed globally. Laboratory assays that can be used for *in vivo* screening of dry beans and other pulses to identify those with the greatest potential to benefit human health are also reported. Sprague–Dawley rats and a diet-induced obesity model in C57Bl/6 mice were used to assess the effect of cooked dry bean incorporated into a purified diet formulation on plasma lipids and hepatic proteins involved in the regulation of lipid biosynthesis. In both animal species, short-term feeding of a bean-containing diet reduced plasma total cholesterol and LDL-cholesterol without affecting HDL-cholesterol or total TAG. Mechanisms associated with cholesterol catabolism and excretion are the likely targets of the bean effect. Unexpectedly, bean-fed obese mice experienced weight loss as well as an improved plasma lipid profile within a 12 d time frame. These findings support the use of short-term (7–14 d) assays to investigate mechanisms that account for the cardioprotective and weight regulatory effects of dry bean and to screen dry bean germplasm resources for types of bean with high protective activity. These same assays can be used to identify the bioactive components of bean that account for the observed effects.

Key words: Dry bean (*Phaseolus vulgaris* L.): CVD: Cholesterol: HDL-cholesterol: LDL-cholesterol: Body weight: Diet-induced obesity

A wide variety of legumes such as dry grain pulses, soybeans and peanuts are consumed in the human diet. Of these, the dry grain pulses have played a significant role throughout civilisation as a primary source of macronutrients, particularly protein, when combined with cereal grains. According to the FAO, the ideal ratio of cereal grains to pulses in the diet is 2:1, which is considerably different from the current consumption ratio of 8:1⁽¹⁾. Interest in pulses is reawakening because they are particularly well suited to emerging global concerns about food security in an ecologically and energy sustainable manner^(2,3). Of the four pulses that are prominent staple foods, i.e. dry beans, dry peas, chickpeas and lentils, dry bean (*Phaseolus vulgaris* L.) is the most widely produced and consumed non-processed legume and was the focus of the experiments reported herein⁽¹⁾.

Numerous studies indicate that dry bean consumption is associated with lower rates of chronic diseases such as CVD, type-2 diabetes and cancer^(4–13). The cardioprotective activity of dry bean consumption is primarily attributed to its effect on cholesterol metabolism^(13–17). A recent meta-analysis found that the net change in total cholesterol for individuals treated

with a pulse diet compared to control was -118 mg/l; mean net change in LDL-cholesterol (LDL-C) was -80 mg/l⁽¹⁶⁾. Consistent with these reports, cholesterol-lowering activity has also been observed in animal models of diet-induced hypercholesterolaemia using rats or pigs^(18–23). In those studies, the effects of dry bean on multiple aspects of cholesterol metabolism were investigated. A reduction in plasma cholesterol of 15–20% was observed at dietary bean concentrations of 30% w/w on a DM basis, which is equivalent to about twice as much bean as is consumed in parts of Africa, particularly Burundi, where annual per-capita intake has been reported to be 40 kg⁽¹⁾. To put this observation in perspective, worldwide consumption varies considerably, ranging from 2 to 3.5 kg/capita per year in Europe and the United States to the 40 kg/capita per year in Burundi^(1,24). While the clinical effects on cholesterol metabolism summarised in the meta-analysis⁽¹⁶⁾ and the work conducted in animal models both indicate that the effects of dry bean and other pulses on the plasma lipid profile associated with reduced CVD risk are modest at currently recommended levels of consumption⁽²⁵⁾, differences among dry bean cultivars in

Abbreviations: CYP7A, cytochrome P-450 cholesterol 7 α hydroxylase; LDL-C, LDL-cholesterol.

* **Corresponding author:** H. J. Thompson, fax +1 970 491 1004, email henry.thompson@colostate.edu

cholesterol-lowering activity have been observed^(16,20,21). This fact is largely unappreciated, and yet provides an avenue for increasing dry bean's clinical impact via the identification of cultivars of dry bean and other pulses with markedly higher levels of cardioprotective activity. That the differences among cultivars of bean in health benefits can be systematically exploited, is supported by a recent report that dry bean types have significantly different cancer inhibitory activity and that differences in activity are associated with the genetic heritage of the beans⁽²⁶⁾. As outlined in reference⁽²⁷⁾, our laboratory has been working to encourage biomedical and agricultural scientists to work together to improve staple food crops such as pulses for their biomedical traits. For this to occur, it is essential to develop *in vivo* models for defining mechanisms and for translating those mechanisms to assays that can be used to screen the large number of genetically diverse dry bean varieties that are consumed in different regions of the world.

The initial objective of the present study was to determine if the effects of dietary dry bean on plasma cholesterol could be assessed in a 1-week animal feeding study. The approach reported is based on a 7 d experiment in which the safety of graded dietary levels of cooked bean were assessed in rat liver using a gene expression array⁽²⁸⁾. Transcript expression profiling revealed a dose-dependent induction of cytochrome P-450 cholesterol 7 α hydroxylase (CYP7A). Since the enzyme encoded by this gene is a rate-limiting enzyme in the synthesis of bile acid from cholesterol and is involved in the regulation of cholesterol excretion by catalysing the formation of 7- α -hydroxysterol, we hypothesised that the same 1-week feeding study design could be used to evaluate the effects of dry bean on cholesterol metabolism. Based on initial findings consistent with this hypothesis, the work was expanded in two directions: (1) assessment of the effects of dry bean feeding on the activity of key enzymes that regulate lipid metabolism in rats; (2) the evaluation of dry bean effects on cholesterol metabolism in mice that were induced to be obese by feeding a high-fat diet.

Research design and methods

Experimental animals

Experiment 1. For this experiment, 19-d-old female Sprague–Dawley rats (*n* 42) were obtained from Taconic Farms and housed in a room maintained at 25°C with 30% relative humidity and a 12 h light–12 h dark cycle. Animals were fed a standard laboratory animal diet American Institute of Nutrition (AIN)-93-G⁽²⁹⁾ until 27 d of age, followed by feeding of the experimental diets from 27 to 34 d of age. Rats were randomised to one of five groups that consumed diets containing: 0% (*n* 18), 7.5% (*n* 6), 15% (*n* 6), 30% (*n* 6) or 60% (*n* 6) w/w dry red bean powder.

Experiment 2. For this experiment, sixteen female Sprague–Dawley rats (Taconic Farms), 27 d of age, were randomly divided into two groups (*n* 8) and fed one of two diets containing 0 or 60% (w/w) dry bean for 7 d. The diet formulation was as described in Expt 1.

Experiment 3. For this experiment, forty C57BL/6j male mice fed an obesogenic high-fat diet from birth were obtained

from Jackson Laboratory at 9 months of age. Mice were randomised to one of two dietary groups and fed 0% (*n* 20) or 46.5% (*n* 20) (w/w) dry bean in the high-fat diet (formulation in Table 1) for 12 d.

Experiment 4. For this experiment, eighteen C57BL/6j male mice, fed an obesogenic high-fat diet from birth were obtained from Jackson Laboratory at 9 months of age. Mice were randomised to one of three groups and assigned to the high-fat diet containing: 0% (*n* 6), 30% (w/w) dry bean (formulation in Table 1). Next, six mice were assigned to a low-fat diet (Research Diets formulation D12329). The experimental feeding was for 7 weeks. The work for all animal experiments reported was reviewed and approved by the Institutional Animal Care and Use Committee and conducted according to the committee guidelines.

Experimental diets

The diet formulation for Expts 1 and 2 was a modification of standard AIN-93-G diets (16.28 kJ/g (3.89 kcal/g)), and identical to the formulation used previously⁽³⁰⁾. The diet formulation used for Expts 3 and 4 is shown in Table 1. Dry bean (market class: small red) was provided by Archer Daniels Midland Company and was sent to Bush Brothers & Company for canning. Cooked beans were packed in standard brine without the incorporation of any additives. Beans were then sent to Van Drunen Farms where the beans were drained and freeze-dried. The freeze-dried bean was then milled into a homogeneous powder and sent to our laboratory and stored at –20°C until incorporated into diets. Diets were formulated using specific guidelines⁽²⁹⁾ and adjusted using the proximate analysis of the bean powders (Warren Analytical). The diets were formulated to match macronutrient levels (i.e. protein, carbohydrate and crude fibre) across the diet groups. The differences in macronutrient composition were balanced with purified diet components. The percentage of dry bean incorporated into the diets is expressed as mass of bean powder in g/100 g of total diet. Control diets consisted of 7.5% crude fibre to correspond to the dry bean diets.

Table 1. High-fat diet composition*

	Control (g/100 g)	30%	46.5%
Bean	0.0	30.0	46.5
Casein	22.8	15.9	12.1
Dextrose	17.0	0.0	0.0
Sucrose	17.5	12.6	0.0
Soyabean oil	2.5	2.5	2.5
Coconut oil	33.35	33.4	33.35
Solka-Floc	1.35	0.17	0.0
L-Try	0.0	0.00	0.005
DL-Met	0.3	0.3	0.3
Choline bitartrate	0.2	0.2	0.2
Vitamin mix†	1.0	1.0	1.0
Mineral mix‡	4.0	4.0	4.0

*The energy density of each diet was: 19.79, 21.92 or 23.26 kJ/g (4.73, 5.24 or 5.56 kcal/g) for the control, 30 and 46.5% w/w rat diets, respectively.

†Vitamin mix AIN-93-VX⁽²⁹⁾.

‡Mineral mix AIN-93-MX⁽²⁹⁾.

Study diets consisted of the standard diet with ground cooked red bean powder added to make up 7.5, 15, 30 or 60% w/w of the diet for rat and 30 or 46.5% red bean in high-fat diet formula for mice. Casein and maize starch were adjusted to maintain similar macronutrient content across red bean dosage group as previously published⁽³¹⁾. At all times during the study, animals had *ad libitum* access to food and water.

Necropsy

Necropsy occurred after the rats had received the experimental diets for 7 d in Expts 1 and 2 and after the mice had received the experimental diets for 14 d (Expt 3) or 49 d (Expt 4). Animals were killed via inhalation of gaseous CO₂ followed by cervical dislocation, and the sequence in which the animals were euthanised was stratified across groups so as to minimise the likelihood that order effects would masquerade as treatment-associated effects. After the animals lost consciousness, blood was directly obtained from the retro-orbital sinus and gravity-fed through heparinised capillary tubes (Fisher Scientific) into EDTA coated tubes (Becton Dickinson). In Expts 1 and 2, the livers were immediately removed after plasma collection, freeze-clamped in liquid N₂ and stored at -80°C.

Body weight analysis

Animals in all experiments were weighed three times per week. The AUC of body weight was generated using GraphPad Prism 5 software (La Jolla, CA, USA) and analysed by Systat statistical analysis software, version 12 (Chicago, IL).

Plasma lipids analysis

Total cholesterol, HDL-cholesterol and TAG in plasma were determined enzymatically using a commercially available kit (Pointe Scientific, Inc.). Plasma LDL-C was calculated using the following formula: LDL-C = total cholesterol - (HDL-cholesterol + (TAG/5))⁽³²⁾.

Plasma hormones and cytokines analysis

Insulin-like growth factor-1, insulin, leptin, IL-6 and TNF- α in plasma were determined using a commercially available ELISA or Multiplex kits (Millipore).

Western blotting analysis

Antibodies. Primary antibodies used in this study were anti-phospho-acetyl-CoA carboxylase, anti-acetyl-CoA carboxylase, anti-fatty acid synthase and anti-rabbit Ig-horseradish peroxidase-conjugated secondary antibody, as well as LumiGLO reagent with peroxide, all from Cell Signaling Technology. Anti-3-hydroxyl-3-methylglutaryl-CoA reductase, anti-stearoyl-CoA desaturase, anti-sterol regulatory element binding protein 1, anti-CYP7A and anti-goat Ig-horseradish peroxidase-conjugated secondary antibody were from Santa Cruz

Chemicals. Mouse anti- β -actin primary antibody was obtained from Sigma Chemical Company.

Liver tissues were homogenised in lysis buffer (40 mM-Tris-HCl (pH 7.5), 1% Triton X-100, 0.25 M-sucrose, 3 mM-ethylene glycol tetraacetic acid (EGTA), 3 mM-EDTA, 50 μ M- β -mercaptoethanol, 1 mM-phenyl-methylsulfonyl fluoride and complete protease inhibitor cocktail (Calbiochem)). The lysates were centrifuged at 7500 g for 10 min in a tabletop centrifuge at 4°C and clear supernatant fractions were collected and stored at -80°C. The protein concentration in the supernatants was determined by the Bio-Rad protein assay (Bio-Rad).

Western blotting was performed as described previously⁽³³⁾. Briefly, protein lysate was subjected to 8–16% SDS-PAGE and the proteins were transferred to a nitrocellulose membrane. The levels of phospho-acetyl-CoA carboxylase (Ser79), acetyl-CoA carboxylase, 3-hydroxyl-3-methylglutaryl-CoA reductase, fatty acid synthase, stearoyl-CoA desaturase, sterol regulatory element binding protein 1 and β -actin were determined using specific primary antibodies, followed by treatment with the appropriate peroxidase-conjugated secondary antibodies and visualised by LumiGLO reagent Western blotting detection system. The chemiluminescence signal was captured using a ChemiDoc densitometer (Bio-Rad) that is equipped with a charge-coupled device camera having a resolution of 1300 \times 1030 and run under the control of Quantity One software (Bio-Rad) and analysed by the software. The actin-normalised scanning density data were reported.

Statistical analysis

Body weight, Lee Index (a measure of body fatness that parallels BMI in human; (body mass (g)^{0.33}/nasoanal length (cm)) and plasma lipids, hormones and cytokines were analysed using ANOVA (repeated-measures ANOVA for body weight) followed by Bonferroni *post hoc* test. For Western blots, the data shown in the tables were either the actin-normalised scanning data for proteins or the ratio of the actual scanning units derived from the densitometric analysis of each Western blot for the phospho-proteins. For statistical analyses, the actin-normalised scanning density data obtained from the ChemiDoc scanner using Quantity One (Bio-Rad) were rank-transformed, an approach that is particularly suitable for semi-quantitative measurements that are collected as continuously distributed data as is the case with Western blots. The ranked data were then subjected to multivariate ANOVA⁽³⁴⁾. Ratio data were computed from the scanning units derived from the densitometric analysis, i.e. the arbitrary units of optical density for variables stated and then the ratios were rank-transformed and evaluated via multivariate ANOVA. All analyses were performed using Systat statistical analysis software, version 12.

Results

Experiment 1

This study was conceived based on the observation that dietary cooked bean induced a dose-dependent increase in transcript levels of CYP7A in the liver, one of the proteins

Table 2. Effect of dietary bean (7 d) on plasma lipid profile and liver cytochrome P-450 cholesterol 7 α hydroxylase (CYP7A) in rats (Mean values with their standard errors)

Dietary beans (%)	TC (mmol/l)		HDL-C (mmol/l)		HDL-C/TC (%)		LDL-C (mmol/l)		TAG (mmol/l)		CYP7A* (AUOD)	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
0	2.17 ^a	0.05	1.37 ^a	0.05	63 ^a	2	0.62 ^a	0.05	0.85 ^{a,b}	0.06	122 ^a	13
7.5	2.33 ^a	0.10	1.50 ^a	0.13	65 ^a	4	0.59 ^{a,b}	0.08	1.13 ^a	0.14	89 ^a	1
15	2.17 ^{a,c}	0.08	1.42 ^a	0.08	65 ^a	4	0.54 ^{a,b}	0.10	1.11 ^a	0.08	112 ^a	9
30	1.91 ^{b,c}	0.08	1.29 ^a	0.05	67 ^a	2	0.49 ^{a,b}	0.05	0.64 ^b	0.05	135 ^a	13
60	1.81 ^b	0.10	1.29 ^a	0.10	70 ^a	2	0.39 ^b	0.05	0.78 ^{a,b}	0.09	228 ^b	39
<i>P</i>	<0.0001		0.354		0.383		0.030		0.005		0.003	

TC, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; AUOD, arbitrary units of optical density.

^{a,b,c} Mean values within a column with unlike superscript letters were significantly different among those of dry beans ($P < 0.05$; ANOVA with *post hoc* comparisons by the method of Bonferroni).

* Values ($\times 10^3$) are determined by Western blotting.

that regulates cholesterol saturation of bile acids⁽²⁸⁾. Induction of CYP7A was predicted to result in a dose-dependent reduction in plasma cholesterol. As shown in Table 2, total plasma cholesterol decreased with increasing dietary bean, although the decrease was only statistically significant at the highest two dietary concentrations. This observation is in agreement with earlier reports of cholesterol-lowering in a rat model of diet-induced hypercholesterolaemia as well as in a similar hypercholesterolaemia model that was implemented in the pig^(18–23). Interestingly, the magnitude of cholesterol-lowering in the earlier studies that were of longer duration was of the order of 15–20%. This reduction is comparable to that reported in Table 2. It is well known that the rat metabolises cholesterol differently than the human, given that it has low cholesteryl ester transport protein and high phospholipid transfer protein^(35,36). Plasma HDL concentrations are regulated by and correlated inversely with plasma cholesteryl ester transport protein⁽³⁷⁾. Consequently, rats transport most of their cholesterol in the HDL fraction. This fraction is known to be refractory to alteration^(38–40), as was observed in the response shown in Table 2. On the other hand, LDL-C was reduced by bean feeding, an observation consistent with clinical findings⁽¹⁶⁾. Also noted in Table 2 is an effect of bean feeding on plasma TAG, although given the bi-phasic nature of this response, the biological significance of the changes observed is unclear.

Based on these observations, livers from the rats were probed for levels of CYP7A protein using a polyclonal rabbit antibody. As shown in Table 2, there was a graded increase in protein with higher levels of dietary bean, but the change was significant only at the highest dietary concentration. To further evaluate the observation of increased levels of CYP7A in the liver, plasma total cholesterol concentration was regressed on the hepatic concentration of CYP7A protein. An inverse relationship was observed, but it was not significant (r^2 0.04, $P=0.78$). These results are not consistent with a causal relationship between induction of CYP7A and the observed reduction in plasma total cholesterol.

Experiment 2

Based on the results of Expt 1, the scope of mechanistic inquiry was broadened to determine if bean feeding was

affecting lipid biosynthesis. The proteins selected for analysis are enzymes that control key steps in lipid biosynthesis in the liver. As shown in Table 3, while there was a pattern of protein expression consistent with the down-regulation of lipid biosynthesis, none of the differences was statistically significant. While this does not rule out the existence of differences in enzyme activity, the finding is consistent with the focus placed on cholesterol elimination and bile acid degradation in previous efforts to identify the cholesterol-lowering mechanisms associated with dry bean feeding^(18–23).

Experiment 3

In Expts 1 and 2, there was no manipulation of cholesterol metabolism by feeding dietary cholesterol. This approach was in marked contrast to what has been reported in the literature, where the effects of bean feeding were assessed on diet-induced hypercholesterolaemia^(18–23). To complement both approaches, work was extended to a diet-induced obesity model. Wild-type C57Bl/6 mice are highly susceptible to diet-induced obesity and the obesity syndrome that results is associated with alterations in lipid metabolism characteristic of metabolic syndrome, a risk factor for CVD^(41–46).

To initiate this experiment, obese mice that had been on an obesogenic high-fat diet throughout their lives were

Table 3. Effects of dry bean (7 d) on key regulatory proteins in lipid metabolism of rats (Mean values with their standard errors)

Proteins	Control		Dry bean		<i>P</i>
	Mean	SEM	Mean	SEM	
pACC ^{Ser79}	2016 ^a	336	1390 ^a	126	0.106
ACC	2371 ^a	195	1331 ^b	197	0.003
pACC/ACC	0.96 ^a		1.34 ^a		0.285
HMGCR	570 ^a	27	615 ^a	52	0.453
FASN	2347 ^a	350	1874 ^a	159	0.242
SCD	101 ^a	11	96 ^a	7	0.732
SREBP1	147 ^a	28	124 ^a	28	0.564

pACC^{Ser79}, phospho-acetyl-CoA carboxylase with phosphorylation at site of Ser⁷⁹; ACC, acetyl-CoA carboxylase; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; FASN, fatty acid synthase; SREBP1, sterol regulatory element binding protein-1.

^{a,b} Mean values within a row with unlike superscript letters were significantly different between control and 60% (w/w) dry bean ($P < 0.05$; ANOVA).




Fig. 1. Growth curves of mice fed either high-fat control (HF CTRL, \circ) or high-fat 60% (w/w) small red dry bean (HF 60% SR, \bullet) for 12 d. Values are means, with their standard errors for each point represented by vertical bars (n 20). The growth curves were statistically different ($P < 0.05$; repeated-measures ANOVA). *From 5 d post experimental diet until the end of the experiment, significant differences between HF CTRL and HF 60% SR were observed ($P < 0.05$).

obtained from the vendor. The same high-fat diet formulation used by the vendor was modified as detailed in Table 1 to contain 46.8% w/w bean, the maximum amount that could be incorporated into this formulation. As shown in Fig. 1, the initial results were quite unexpected. The obese mice fed the high-fat bean diet lost weight throughout the 12 d feeding study. Recognising the potential importance of the observation, body length was measured at necropsy and the Lee Index, a measure of adiposity, was computed⁽⁴⁷⁾. As shown in Table 4, body weight and Lee Index were reduced by bean feeding. Total plasma cholesterol and LDL-C were reduced in bean-fed mice in comparison to the high-fat control group. As anticipated, treatment effects were not observed on either HDL-cholesterol or TAG, a finding consistent with

the widely reported resistance of these measures to change in the mouse, an aspect of cholesterol metabolism that distinguishes mice from humans^(38,39). While recognising that the mouse is resistant to atherogenesis and that mice differ from humans in their metabolism of cholesterol, developing an assessment model using the mouse is attractive. The availability of genetically engineered mouse models affords an unprecedented opportunity to evaluate causal relationships and C57Bl/6 are commonly used to create these engineered mouse models⁽³⁹⁾.

Experiment 4

This study was undertaken to confirm the findings in Expt 3 that bean had effects on body weight regulation and plasma cholesterol. In this experiment, bean dose was reduced to 30% w/w. Fig. 2 confirms that bean feeding resulted in initial weight loss in obese mice. In order to determine if the effect persisted over time, the impact on body weight was assessed for 7 weeks. While there was plateauing of the weight loss effect and some degree of recovery, a difference in body weights was maintained. Included in this experiment was a negative control group. These animals were switched to a low-fat diet at the same time that bean feeding was initiated. This change has been reported to result in weight loss, a finding confirmed in this experiment^(41–46). As shown in Fig. 2, the bean-fed and negative control groups had a similar pattern of weight change. The negative control provides an example of the growth pattern for which dry bean varieties can be screened. Table 4 quantifies these effects. Bean feeding reduced weight relative to the high-fat control group over the course of the experiment, but the 4 g difference in final body weights between groups was not statistically significant. Nonetheless, the body composition of the bean-fed mice was shifted to a less obese state as indicated by the reduction in the Lee Index and lower plasma leptin,

Table 4. Effects of dietary dry bean (12 d) on body weight and plasma lipid profile in the mouse (Mean values with their standard errors)

Dietary treatment	High-fat control		High-fat bean		P	Low-fat reference*	
	Mean	SEM	Mean	SEM		Mean	SEM
Initial body weight (g)	55 ^a	1	54 ^a	1	0.432	34	1
Final body weight (g)	56 ^a	1	51 ^b	1	0.001	34	1
Net body weight area change† (g)	5.4 ^a	2.1	-17.7 ^b	2.1	<0.0001	-0.3	1
Lee Index‡ (g ^{0.33} /cm)	0.328 ^a	0.002	0.321 ^a	0.002	0.016	0.292	0.003
TC (mg/l)	57.2 ^a	2.3	47.6 ^b	0.8	0.002	27.7	2.8
HDL-C (mg/l)	28.2 ^a	0.8	27.9 ^a	1.0	0.906	14.2	1.6
HDL-C/TC (%)	50 ^a	1	59 ^b	2	<0.0001	51	2
LDL-C (mg/l)	23.5 ^a	2.1	14.0 ^b	1.0	<0.0001	9.8	2.1
TAG (mg/l)	12.1 ^a	0.7	12.1 ^a	0.6	0.928	7.7	0.6

TC, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.

^{a,b}Mean values within a row with unlike superscript letters were significantly different between high-fat control and high-fat bean ($P < 0.05$; ANOVA).

*Mice in this group were fed a low-fat diet (Research Diets: D12923) from weaning. They were age-matched to the mice fed a high-fat diet and were maintained in the same animal holding room. These mice were not included in the statistical analyses presented in this table.

†Net body weight area changes were generated from area under body weight curves after comparing the body weight on different days of the experimental diet treatment using GraphPad Prism 5 software.

‡Lee Index was calculated according to the formula, Lee Index = (body weight (g))^{0.33}/(nose-to-anus length (cm))⁽⁴⁷⁾.




Fig. 2. Growth curves of mice fed high-fat (HF, ○) diet, HF diet including 46.5% (w/w) small red bean (SR, ●), or low-fat diet switched from HF diet (HF-LF, △) for 7 weeks. Values are means, with their standard errors for each point represented by vertical bars (*n* 8). The growth curves among groups were significantly different (*P*<0.05; repeated-measures ANOVA). HF, SR or HF-LF growth curves were significantly different from each other (*P*<0.05 for each paired comparison; *post hoc* comparisons by the method of Bonferroni).

an indicator of adipocyte mass^(47,48). As in Expts 1–3, plasma total cholesterol (*P*=0.032) and LDL-C (trend *P*=0.067) were also reduced in the bean-fed obese mice.

Discussion

The traditional approach in experimental nutrition has been to conduct 28d animal feeding studies in order to assess the effects of a dietary intervention. This approach has served the field well; however, the use of shorter time frames, frequently 7–14d in duration, is increasing and has been reported to have greater sensitivity to detect cellular and molecular responses that might otherwise go unobserved⁽⁴⁹⁾. Other than this enhanced sensitivity, short-term feeding studies have the inherent benefit of reducing the amount of

material needed for evaluation as well as the time and cost of an experiment. These considerations led to the design of the short-duration experiments reported in this investigation.

In the present study, two rodent models involving rats or mice were used to investigate the effect of consumption of cooked dry bean incorporated into a purified diet formulation on aspects of lipid metabolism associated with CVD risk. Clear evidence was obtained that dietary bean reduced circulating levels of total cholesterol and LDL-C in rats and mice. An initial screening of rat liver for the effects of dry bean on regulatory enzymes involved in fatty acid or cholesterol biosynthesis was negative, indicating that a focus on cholesterol and bile acid secretion and degradation in the gut should receive priority in future studies of mechanism. Our results indicate that a very simple 7d feeding study with plasma total cholesterol as an endpoint can be used for screening bean varieties. To illustrate the intent of screening for cardioprotective activity, the objective would be to identify cultivars that give the same effect on plasma cholesterol at 7.5% w/w in the diet as the 60%w/w concentrations of bean reported in Table 2.

The effect of dry bean feeding was also assessed in a mouse model of diet-induced obesity that is being used by many laboratories to gain insights into disease mechanisms associated with obesity. The finding that bean feeding not only lowered total cholesterol (*P*=0.032) and LDL-C (*P*=0.067), but also had anti-obesogenic activity is of potential interest. The observed effects on change in body weight and body composition were unexpected because we have not observed dry bean to affect weight gain in non-obese rats⁽³¹⁾. Despite the fact that no previous reports of such an effect were found in the literature, the observed changes in body weight and body fat as reflected in the Lee Index and plasma leptin data are plausible, given the evidence that bean feeding can alter the gut microbiome⁽¹⁴⁾ and that such changes have been reported to influence body weight regulation and obesity^(44–46,50) (Table 5).

Table 5. Effects of dietary beans (7-week) on body weight and plasma lipid profile in the mouse (Mean values with their standard errors, *n* 6)

Dietary treatment	High-fat control		High-fat bean		<i>P</i>
	Mean	SEM	Mean	SEM	
Initial body weight (g)	48.6 ^a	2.2	48.6 ^a	1.8	0.990
Final body weight (g)	54.4 ^a	0.8	51.0 ^a	2.4	0.120
Net body weight area change* (g)	148 ^a	41	–17 ^b	42	0.009
Lee Index (g ^{0.33} /cm)†	0.319 ^a	0.004	0.308 ^b	0.004	0.037
TC (mmol/l)	5.28 ^a	0.39	4.32 ^b	0.28	0.032
HDL-C (mmol/l)	2.64 ^a	0.23	2.53 ^a	0.13	0.637
HDL-C/TC (%)	51 ^a	6	60 ^a	5	0.127
LDL-C (mmol/l)	2.15 ^a	0.47	1.27 ^a	0.28	0.067
TAG (mmol/l)	1.12 ^a	0.05	1.10 ^a	0.07	0.392
Plasma leptin (nmol/l)	1.11 ^a	0.21	0.69 ^b	0.08	0.034

TC, cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol.

^{a,b} Mean values within a row with unlike superscript letters were significantly different between high-fat control and high-fat bean (*P*<0.05; one-tailed *t* test).

* Net body weight area changes were generated from area under body weight curves after comparing the body weight on different days of the experimental diet treatment using GraphPad Prism 5 software.

† Lee Index was calculated according to the formula, Lee Index = (body weight (g))^{0.33}/(nose-to-anus length (cm))⁽⁴⁷⁾.

Summary and conclusions

While the effect of dry bean consumption on whole-body energetics requires additional scrutiny, these observations have the potential to draw together two seemingly unrelated global issues, the obesity pandemic that if unabated will wreak social and economic havoc globally because of the associated increase in chronic diseases that accompany obesity, and the emerging crisis in global food security that will undoubtedly refocus attention on the role of pulses as a staple food crop.

Acknowledgements

The present study was supported in part by USAID grant no. REE-A-00-03-00094-00, the Bean Health Alliance, and United States Department of Agriculture National Institute of Food and Agricultural Agriculture and Food Research Initiative Project no.: 2009-01929. The authors thank Amanda Blasingame, Erica Danielle, John McGinley, Angie Neil, Elizabeth Neil and Denise Rush for their excellent technical assistance. Z. Z. and W. J. conducted the analyses of plasma and tissue and participated in data evaluation. H. J. T. designed the experiments and assisted with data evaluation; and also provided oversight of all aspects of the experiment. All authors participated in the writing of the manuscript. The authors declare that there are no conflicts of interest.

References

1. Faostat, Food and Agriculture Organization (2009) <http://faostat.fao.org>
2. World Health Organization (2003) *Diet, Nutrition and the Prevention of Chronic Disease. Report of a Joint WHO/FAO Consultation* no. 916. Geneva: WHO.
3. World Health Organization (2007) *The World Health Report 2007: A Safer Future, Global Public Health Security in the 21st Century*. Geneva: WHO.
4. Adebamowo CA, Cho E, Sampson L, *et al.* (2005) Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. *Int J Cancer* **114**, 628–633.
5. Anderson JW & Gustafson NJ (1988) Hypocholesterolemic effects of oat and bean products. *Am J Clin Nutr* **48**, 749–753.
6. Anderson JW, Gustafson NJ, Spencer DB, *et al.* (1990) Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans. *Am J Clin Nutr* **51**, 1013–1019.
7. Bobe G, Barrett KG, Mentor-Marcel RA, *et al.* (2008) Dietary cooked navy beans and their fractions attenuate colon carcinogenesis in azoxymethane-induced ob/ob mice. *Nutr Cancer* **60**, 373–381.
8. Finley JW, Burrell JB & Reeves PG (2007) Pinto bean consumption changes SCFA profiles in fecal fermentations, bacterial populations of the lower bowel, and lipid profiles in blood of humans. *J Nutr* **137**, 2391–2398.
9. Hangen L & Bennink MR (2002) Consumption of black beans and navy beans (*Phaseolus vulgaris*) reduced azoxymethane-induced colon cancer in rats. *Nutr Cancer* **44**, 60–65.
10. Kabagambe EK, Baylin A, Ruiz-Narvarez E, *et al.* (2005) Decreased consumption of dried mature beans is positively associated with urbanization and nonfatal acute myocardial infarction. *J Nutr* **135**, 1770–1775.
11. Lanza E, Hartman TJ, Albert PS, *et al.* (2006) High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the polyp prevention trial. *J Nutr* **136**, 1896–1903.
12. Mentor-Marcel RA, Bobe G, Barrett KG, *et al.* (2009) Inflammation-associated serum and colon markers as indicators of dietary attenuation of colon carcinogenesis in ob/ob mice. *Cancer Prev Res (Phila Pa)* **2**, 60–69.
13. Winham DM, Hutchins AM & Johnston CS (2007) Pinto bean consumption reduces biomarkers for heart disease risk. *J Am Coll Nutr* **26**, 243–249.
14. Bennink MR & Rondini E *Beans and Health: A Comprehensive Review*. Frazee, MN: The Bean Institute; available at <http://beaninstitute.com/wp-content/uploads/2010/01/Bennink-and-Rondini-article.pdf>.
15. Geil PB & Anderson JW (1994) Nutrition and health implications of dry beans: a review. *J Am Coll Nutr* **13**, 549–558.
16. Bazzano LA, Thompson AM, Tees MT, *et al.* (2011) Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis* **21**, 94–103.
17. Pittaway JK, Ahuja KD, Cehun M, *et al.* (2006) Dietary supplementation with chickpeas for at least 5 weeks results in small but significant reductions in serum total and low-density lipoprotein cholesterol in adult women and men. *Ann Nutr Metab* **50**, 512–518.
18. Costa NM, Walker AF & Low AG (1993) The effect of graded inclusion of baked beans (*Phaseolus vulgaris*) on plasma and liver lipids in hypercholesterolaemic pigs given a Western-type diet. *Br J Nutr* **70**, 515–524.
19. Costa NM, Low AG, Walker AF, *et al.* (1994) Effect of baked beans (*Phaseolus vulgaris*) on steroid metabolism and non-starch polysaccharide output of hypercholesterolaemic pigs with or without an ileo-rectal anastomosis. *Br J Nutr* **71**, 871–886.
20. Dabai FD, Walker AF, Sambrook IE, *et al.* (1996) Comparative effects on blood lipids and faecal steroids of five legume species incorporated into a semi-purified, hypercholesterolaemic rat diet. *Br J Nutr* **75**, 557–571.
21. Rosa CO, Costa NM, Nunes RM, *et al.* (1998) The cholesterol-lowering effect of black, cariouinha and red beans (*Phaseolus vulgaris* L.) in hypercholesterolemic rats. *Arch Latinoam Nutr* **48**, 306–310.
22. Rosa CO, Costa NM, Leal PF, *et al.* (1998) The cholesterol-lowering effect of black beans (*Phaseolus vulgaris* L.) without hulls in hypercholesterolemic rats. *Arch Latinoam Nutr* **48**, 299–305.
23. Sarathy R & Saraswathi G (1983) Effect of tender cluster bean pods (*Cyamopsis tetragonoloba*) on cholesterol levels in rats. *Am J Clin Nutr* **38**, 295–299.
24. Mitchell DC, Lawrence FR, Hartman TJ, *et al.* (2009) Consumption of dry beans, peas, and lentils could improve diet quality in the US population. *J Am Diet Assoc* **109**, 909–913.
25. U.S. Department of Health and Human Services (2005) Dietary Guidelines for Americans. <http://www.healthierus.gov/dietaryguidelines>
26. Thompson MD, Brick MA, McGinley JN, *et al.* (2009) Chemical composition and mammary cancer inhibitory activity of dry bean. *Crop Sci* **49**, 179–186.
27. Thompson MD & Thompson HJ (2009) Biomedical agriculture: a systematic approach to food crop improvement for chronic disease prevention. In *Advances in Agronomy*,



- pp. 1–54 [D Sparks, editor]. **102**, San Diego, CA: Academic Press. *British Journal of Nutrition* (submitted).
28. Daniell EL, Ryan E, Brick MA, *et al.* (2011) Dietary dry bean effects on hepatic expression of stress and toxicity related genes in rats.
 29. Reeves PG, Nielsen FH & Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition *ad hoc* writing committee on the reformulation of the AIN-76A rodent diet. *J Nutr* **123**, 1939–1951.
 30. Thompson MD, Brick MA, McGinley JN, *et al.* (2009) Chemical composition and cancer inhibitory activity of dry bean market classes. *Crop Sci* **49**, 179–186.
 31. Thompson MD, Thompson HJ, Brick MA, *et al.* (2008) Mechanisms associated with dose-dependent inhibition of rat mammary carcinogenesis by dry bean (*Phaseolus vulgaris* L.). *J Nutr* **138**, 2091–2097.
 32. Balal M, Paydas S, Inal T, *et al.* (2010) Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol in renal transplant recipients. *Ren Fail* **32**, 455–458.
 33. Jiang W, Zhu Z & Thompson HJ (2003) Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. *Cancer Res* **63**, 1228–1234.
 34. Morrison DF (1990) *Multivariate Statistical Methods*, 3rd ed. New York, NY: McGraw-Hill Publishing Co.
 35. Cheung MC, Wolfbauer G & Albers JJ (1996) Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. *Biochim Biophys Acta* **1303**, 103–110.
 36. Guyard-Dangremont V, Desrumaux C, Gambert P, *et al.* (1998) Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. *Comp Biochem Physiol B Biochem Mol Biol* **120**, 517–525.
 37. Tsutsumi K, Hagi A & Inoue Y (2001) The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. *Biol Pharm Bull* **24**, 579–581.
 38. Turk JR & Laughlin MH (2004) Physical activity and atherosclerosis: which animal model? *Can J Appl Physiol* **29**, 657–683.
 39. Moghadasian MH, Frohlich JJ & McManus BM (2001) Advances in experimental dyslipidemia and atherosclerosis. *Lab Invest* **81**, 1173–1183.
 40. Moghadasian MH (2002) Experimental atherosclerosis: a historical overview. *Life Sci* **70**, 855–865.
 41. Burrage LC, Baskin-Hill AE, Sinasac DS, *et al.* (2010) Genetic resistance to diet-induced obesity in chromosome substitution strains of mice. *Mamm Genome* **21**, 115–129.
 42. Buchner DA, Yazbek SN, Solinas P, *et al.* (2011) Increased mitochondrial oxidative phosphorylation in the liver is associated with obesity and insulin resistance. *Obesity (Silver Spring)* **19**, 917–924.
 43. Millward CA, Burrage LC, Shao H, *et al.* (2009) Genetic factors for resistance to diet-induced obesity and associated metabolic traits on mouse chromosome 17. *Mamm Genome* **20**, 71–82.
 44. Rezzi S, Martin FP, Shanmuganayagam D, *et al.* (2009) Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates. *Exp Gerontol* **44**, 356–362.
 45. Turnbaugh PJ & Gordon JI (2009) The core gut microbiome, energy balance and obesity. *J Physiol* **587**, 4153–4158.
 46. Ley RE, Backhed F, Turnbaugh P, *et al.* (2005) Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* **102**, 11070–11075.
 47. Cox JE, Laughton WB & Powley TL (1985) Precise estimation of carcass fat from total body water in rats and mice. *Physiol Behav* **35**, 905–910.
 48. Hajer GR, van Haften TW & Visseren FL (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. *Eur Heart J* **29**, 2959–2971.
 49. Narasaka S, Endo Y, Fu Z, *et al.* (2006) Safety evaluation of hypoallergenic wheat flour by using a DNA microarray. *Biosci Biotechnol Biochem* **70**, 1464–1470.
 50. Backhed F, Ding H, Wang T, *et al.* (2004) The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci U S A* vol. 101, 15718–15723.